<DOC>
	<DOCNO>NCT00789828</DOCNO>
	<brief_summary>This study evaluate efficacy safety Everolimus treat patient Subependymal Giant Cell Astrocytomas associate Tuberous Sclerosis Complex .</brief_summary>
	<brief_title>Efficacy Safety Everolimus ( RAD001 ) Patients All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex ( TSC ) ( EXIST-1 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>All Ages Definite diagnosis Tuberous Sclerosis accord modify Gomez criterion At least one Subependymal Giant Cell Astrocytoma least 1 cm diameter Evidence SEGA worsening compare prior MRI scan Females child bear potential must use birth control Written inform consent SEGA relate surgery likely required opinion investigator Recent heart attack , cardiac relate chest pain stroke Severely impaired lung function Severe liver dysfunction Severe kidney dysfunction Pregnancy breast feed Current infection History organ transplant Surgery within two month prior study enrollment Prior therapy medication class Everolimus Uncontrolled high cholesterol Uncontrolled diabetes HIV Patients metal implant thus prohibit MRI evaluation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SEGA</keyword>
	<keyword>Tuberous Sclerosis</keyword>
	<keyword>Subependymal Giant Cell Astrocytoma</keyword>
	<keyword>mTOR</keyword>
	<keyword>RAD001</keyword>
	<keyword>Mamalian Target Rapamycin</keyword>
	<keyword>Everolimus</keyword>
	<keyword>TSC</keyword>
</DOC>